Todd Hembrough’s Post

Interested to hear the latest in #PrecisionOncology? I'm excited to share this project from our great team! Hear from Dr. Kyle Strickland and Dr. Rebecca Previs as they discuss the different components of liquid biopsy and current technologies used to isolate circulating tumor cells (CTCs) and cell-free DNA (cfDNA). In this webinar, you will learn the potential clinical implications of liquid biopsies on molecular profiling of tumors for therapy selection, early detection of cancer, drug response and therapy resistance. Watch the video to learn more.

Interested to hear the latest in #PrecisionOncology? Hear from Dr. Kyle Strickland and Dr. Rebecca Previs as they discuss the different components of liquid biopsy and current technologies used to isolate circulating tumor cells (CTCs) and cell-free DNA (cfDNA). In this webinar, you will learn the potential clinical implications of liquid biopsies on molecular profiling of tumors for therapy selection, early detection of cancer, drug response and therapy resistance. Watch the video to learn more.

Read this Annals of Surgical Oncology #FeaturedArticle in which the authors evaluated the association between MammaPrint (70-gene risk of distant metastasis signature) and BluePrint (80-gene molecular subtyping signature) and nodal downstaging. 📃: https://ow.ly/m12b50QgZeK

Interested to hear the latest in #PrecisionOncology? Hear from Dr. Kyle Strickland and Dr. Rebecca Previs as they discuss the different components of liquid biopsy and current technologies used to isolate circulating tumor cells (CTCs) and cell-free DNA (cfDNA). In this webinar, you will learn the potential clinical implications of liquid biopsies on molecular profiling of tumors for therapy selection, early detection of cancer, drug response and therapy resistance. Watch the video to learn more.

Great video reminder from Derek Lyle, MD regarding the #TeamEffort it takes to battle #cancer and improve patient outcomes. Much like #neogenomics, here at #fulgentgenetics we have found our #pathologists and clinical laboratory testing have been vital in providing information to support #oncologists with what are often often difficult diagnostic and treatment decisions. #patientsfirst #informdiagnostics #csilaboratories #fulgentpharma #anatomicalpathology

Interested to hear the latest in #PrecisionOncology? Hear from Dr. Kyle Strickland and Dr. Rebecca Previs as they discuss the different components of liquid biopsy and current technologies used to isolate circulating tumor cells (CTCs) and cell-free DNA (cfDNA). In this webinar, you will learn the potential clinical implications of liquid biopsies on molecular profiling of tumors for therapy selection, early detection of cancer, drug response and therapy resistance. Watch the video to learn more.

Interested to hear the latest in #PrecisionOncology? Hear from Dr. Kyle Strickland and Dr. Rebecca Previs as they discuss the different components of liquid biopsy and current technologies used to isolate circulating tumor cells (CTCs) and cell-free DNA (cfDNA). In this webinar, you will learn the potential clinical implications of liquid biopsies on molecular profiling of tumors for therapy selection, early detection of cancer, drug response and therapy resistance. Watch the video to learn more.

Interested to hear the latest in #PrecisionOncology? Hear from Dr. Kyle Strickland and Dr. Rebecca Previs as they discuss the different components of liquid biopsy and current technologies used to isolate circulating tumor cells (CTCs) and cell-free DNA (cfDNA). In this webinar, you will learn the potential clinical implications of liquid biopsies on molecular profiling of tumors for therapy selection, early detection of cancer, drug response and therapy resistance. Watch the video to learn more.

Interested to hear the latest in #PrecisionOncology? Hear from Dr. Kyle Strickland and Dr. Rebecca Previs as they discuss the different components of liquid biopsy and current technologies used to isolate circulating tumor cells (CTCs) and cell-free DNA (cfDNA). In this webinar, you will learn the potential clinical implications of liquid biopsies on molecular profiling of tumors for therapy selection, early detection of cancer, drug response and therapy resistance. Watch the video to learn more.

Interested to hear the latest in #PrecisionOncology? Hear from Dr. Kyle Strickland and Dr. Rebecca Previs as they discuss the different components of liquid biopsy and current technologies used to isolate circulating tumor cells (CTCs) and cell-free DNA (cfDNA). In this webinar, you will learn the potential clinical implications of liquid biopsies on molecular profiling of tumors for therapy selection, early detection of cancer, drug response and therapy resistance. Watch the video to learn more.